IQVIA Announces First-Quarter 2025 Financial Results
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
Elecsys PRO-C3: Roche’s Precision Test for Liver Fibrosis
One of the most prevalent causes of chronic liver disease in the developed world, MASLD affects about 30% of the population.
Data From Phase 3 QUASAR Long-term Extension (LTE) Study Shows TREMFYA® (guselkumab) Maintains Sustained Remission in Ulcerative Colitis
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission [Read More…]
Amgen Reports Strong Q1 2025 Results Driven by Robust Volume Growth and Key Product Performance
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]
AstraZeneca Released KALOS and LOGOS Phase III Clinical Trials Result Shows Positive High-level Results of Breztri for Treating Asthma
The purpose of the duplicate, randomized, double-blind KALOS and LOGOS trials was to examine Breztri as a possible asthma medication.
Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth
Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.
Johnson & Johnson’s IMAAVYâ„¢ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
AbbVie’s RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis
Adult GCA can now be treated with RINVOQ (upadacitinib), the first and only oral Janus Kinase (JAK) inhibitor authorized for this purpose.
Roche granted FDA breakthrough device designation for VENTANA TROP2, an AI-driven companion diagnostic for non-small cell lung cancer
The gadget analyzes images using artificial intelligence to achieve a degree of diagnosis accuracy that is not achievable with conventional manual grading techniques.
